BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 15770688)

  • 1. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study.
    Collins LC; Tamimi RM; Baer HJ; Connolly JL; Colditz GA; Schnitt SJ
    Cancer; 2005 May; 103(9):1778-84. PubMed ID: 15770688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.
    Sanders ME; Schuyler PA; Dupont WD; Page DL
    Cancer; 2005 Jun; 103(12):2481-4. PubMed ID: 15884091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis.
    Boyages J; Delaney G; Taylor R
    Cancer; 1999 Feb; 85(3):616-28. PubMed ID: 10091735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
    Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
    Li CI; Malone KE; Saltzman BS; Daling JR
    Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BI-RADS MRI enhancement characteristics of ductal carcinoma in situ.
    Rosen EL; Smith-Foley SA; DeMartini WB; Eby PR; Peacock S; Lehman CD
    Breast J; 2007; 13(6):545-50. PubMed ID: 17983393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
    Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast.
    Hoque A; Lippman SM; Boiko IV; Atkinson EN; Sneige N; Sahin A; Weber DM; Risin S; Lagios MD; Schwarting R; Colburn WJ; Dhingra K; Follen M; Kelloff GJ; Boone CW; Hittelman WN
    Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):249-59. PubMed ID: 11303595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy.
    Meijnen P; Oldenburg HS; Loo CE; Nieweg OE; Peterse JL; Rutgers EJ
    Br J Surg; 2007 Aug; 94(8):952-6. PubMed ID: 17440955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: a population-based case-control study in Sweden.
    Wärnberg F; Bergh J; Zack M; Holmberg L
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):495-9. PubMed ID: 11352860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situ.
    Baltayan A; Naritoku WY; Chaiwun B; Tsao-Wei DD; Groshen S; Hern RA; Gusterson BA; Taylor CR; Imam SA
    Anticancer Res; 2002; 22(5):2933-7. PubMed ID: 12530020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of magnetic resonance imaging in diagnosis and size assessment of in situ and small invasive breast carcinoma.
    Schouten van der Velden AP; Boetes C; Bult P; Wobbes T
    Am J Surg; 2006 Aug; 192(2):172-8. PubMed ID: 16860625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins.
    Dzierzanowski M; Melville KA; Barnes PJ; MacIntosh RF; Caines JS; Porter GA
    J Surg Oncol; 2005 May; 90(2):71-6. PubMed ID: 15844190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytologic diagnosis and grading of ductal carcinoma in situ.
    McKee GT; Tildsley G; Hammond S
    Cancer; 1999 Aug; 87(4):203-9. PubMed ID: 10455208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lobular neoplasia in breast core needle biopsy specimens is associated with a low risk of ductal carcinoma in situ or invasive carcinoma on subsequent excision.
    Renshaw AA; Derhagopian RP; Martinez P; Gould EW
    Am J Clin Pathol; 2006 Aug; 126(2):310-3. PubMed ID: 16891208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast disease: a primer on diagnosis and management.
    Drukker BH
    Int J Fertil Womens Med; 1997; 42(5):278-87. PubMed ID: 9406832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study.
    Collins LC; Baer HJ; Tamimi RM; Connolly JL; Colditz GA; Schnitt SJ
    Cancer; 2006 Sep; 107(6):1240-7. PubMed ID: 16902983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of recurrence after ductal carcinoma in situ of the breast.
    Habel LA; Daling JR; Newcomb PA; Self SG; Porter PL; Stanford JL; Seidel K; Weiss NS
    Cancer Epidemiol Biomarkers Prev; 1998 Aug; 7(8):689-96. PubMed ID: 9718221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy.
    Tunon-de-Lara C; Giard S; Buttarelli M; Blanchot J; Classe JM; Baron M; Monnier B; Houvenaeghel G
    Breast J; 2008; 14(2):135-40. PubMed ID: 18315691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ.
    Huo L; Sneige N; Hunt KK; Albarracin CT; Lopez A; Resetkova E
    Cancer; 2006 Oct; 107(8):1760-8. PubMed ID: 16977650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.